Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.
Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap. This story matters for Finance & Markets readers tracking lending. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. LendingNews curates and briefs the finance & markets stories that matter. Our editorial policy →